Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5273449
Max Phase: Preclinical
Molecular Formula: C57H70N10O10S
Molecular Weight: 1087.31
Associated Items:
ID: ALA5273449
Max Phase: Preclinical
Molecular Formula: C57H70N10O10S
Molecular Weight: 1087.31
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NCCOCCOCCOCCOCCn2cc(CNc3cccc(Cc4c(C)c5ccc(Oc6ncccn6)cc5oc4=O)c3)nn2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C57H70N10O10S/c1-37-47-16-15-46(76-56-59-17-8-18-60-56)32-50(47)77-55(71)48(37)30-40-9-7-10-43(29-40)61-33-44-34-66(65-64-44)20-22-73-24-26-75-28-27-74-25-23-72-21-19-58-52(57(4,5)6)54(70)67-35-45(68)31-49(67)53(69)63-38(2)41-11-13-42(14-12-41)51-39(3)62-36-78-51/h7-18,29,32,34,36,38,45,49,52,58,61,68H,19-28,30-31,33,35H2,1-6H3,(H,63,69)/t38-,45+,49-,52+/m0/s1
Standard InChI Key: ZJMDJYUGCSQAEV-UTQKRDDMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1087.31 | Molecular Weight (Monoisotopic): 1086.4997 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Wang C, Wang H, Zheng C, Li B, Liu Z, Zhang L, Yuan L, Xu P.. (2023) Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells., 14 (1.0): [PMID:36655129] [10.1021/acsmedchemlett.2c00446] |
Source(1):